Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | May 05, 2020 | May 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date May 05, 2020 · Filed May 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 129,052 |
Reported balance
After 2020-05-05 transaction · row 1
1 source rowRow 1 · 2020-05-05 · Exercise / conversion · Acquired 2,270 · Balance 129,052 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-05 · Exercise / conversion · Disposed 2,270 · Balance 0 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: 100% of the restricted stock units vested on May 5, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: 100% of the restricted stock units vested on May 5, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2020 Filed May 7, 2020 23:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015829 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 5, 2020. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 5, 2020. Read SEC document |
| May 05, 2020 Filed May 7, 2020 23:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015829 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 21,720 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-004969 · form4.xml · derivative · entry 3 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,720 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vesed quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 21,720 | $67.72 | $1,470,878.40 |
DisclosureSEC source: 0001127602-20-004969 · form4.xml · nonDerivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,782 F1 · price: Sale prices reported for the transactions reported here range from $67.71 to $67.76. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 21,720 | $19.63 | $426,363.60 |
DisclosureSEC source: 0001127602-20-004969 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 11,848 | $0.00 Strike: $66.07 | $0.00 |
DisclosureSEC source: 0001127602-19-018178 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,848 Underlying: Common Stock · 11,848 shares Expires 2029-05-08 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 8, 2019 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 8, 2020 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-018178 · form4.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,270 Underlying: Common Stock · 2,270 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2020, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2020, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 07, 2019 Filed May 8, 2019 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-017785 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 7, 2019. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 7, 2019. Read SEC document |
| May 07, 2019 Filed May 8, 2019 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-017785 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 19,068 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001127602-19-007332 · form4.xml · derivative · entry 3 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,068 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 6, 2010. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 19,068 | $67.08 | $1,279,073.81 |
DisclosureSEC source: 0001127602-19-007332 · form4.xml · nonDerivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,499 F1 · price: Sale prices reported for the transactions reported here range from $67.07 to $67.10. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 19,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007332 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-017244 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,283 Underlying: Common Stock · 2,283 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2019, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2019, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,496 | $0.00 Strike: $65.69 | $0.00 |
DisclosureSEC source: 0001127602-18-017244 · form4.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,496 Underlying: Common Stock · 9,496 shares Expires 2028-05-09 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from May 9, 2018 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 9, 2019 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-016967 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,241 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 8, 2018. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 8, 2018. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-016967 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 22:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-005574 · form4.xml · derivative · entry 3 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest 100% on the first anniversary date of the grant. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 22:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 60,000 | $77.92 | $4,675,080.00 |
DisclosureSEC source: 0001127602-18-005574 · form4.xml · nonDerivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,258 F1 · price: Sale prices reported for the transactions reported here range from $77.88 to $78.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 22:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 60,000 | $26.62 | $1,596,900.00 |
DisclosureSEC source: 0001127602-18-005574 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 12, 2017 21:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-017987 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,241 Underlying: Common Stock · 2,241 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 10, 2017 Filed May 12, 2017 21:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 10,376 | $0.00 Strike: $66.92 | $0.00 |
DisclosureSEC source: 0001127602-17-017987 · form4.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,376 Underlying: Common Stock · 10,376 shares Expires 2027-05-10 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-017798 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,787 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 9, 2017. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 9, 2017. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-017798 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 33,350 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001127602-17-008730 · form4.xml · derivative · entry 3 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,350 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 20,365 | $69.30 | $1,411,373.92 |
DisclosureSEC source: 0001127602-17-008730 · form4.xml · nonDerivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,471 F1 · price: Sale prices reported for the transactions reported here range from $69.281 to $69.331. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 33,350 | $20.71 | $690,511.75 |
DisclosureSEC source: 0001127602-17-008730 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2016 Filed Dec 6, 2016 00:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Shares · Derivative | 2,149.6611 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-069217 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,149.6611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F2 · shares: An aggregate of 2149.6611 shares were reported in Table II when reporting person acquired the phantom shares. The fractional share of 2.6611 was paid out in cash in connection with the conversion into shares of common stock. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| December 01, 2016 Filed Dec 6, 2016 00:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-069217 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 23:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 12.8985 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-063778 · form4.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,149.6611 Underlying: Common Stock · 12.8985 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 29, 2016 Filed Jul 1, 2016 17:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 12.1378 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-056779 · form4.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,136.7626 Underlying: Common Stock · 12.1378 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 11, 2016 Filed May 13, 2016 23:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,321 | $0.00 Strike: $83.90 | $0.00 |
DisclosureSEC source: 0001127602-16-052224 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,321 Underlying: Common Stock · 7,321 shares Expires 2026-05-11 F3 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 11, 2016 Filed May 13, 2016 23:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-052224 · form4.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,787 Underlying: Common Stock · 1,787 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2016 Filed May 10, 2016 20:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-051673 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2016. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2016. Read SEC document |
| May 06, 2016 Filed May 10, 2016 20:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-051673 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 30, 2016 Filed Apr 1, 2016 19:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 9.8873 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-048097 · form4.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,124.6248 Underlying: Common Stock · 9.8873 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| February 26, 2016 Filed Feb 29, 2016 22:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 6,650 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001127602-16-043917 · form4.xml · derivative · entry 3 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,350 Underlying: Common Stock · 6,650 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| February 26, 2016 Filed Feb 29, 2016 22:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,650 | $90.61 | $602,556.50 |
DisclosureSEC source: 0001127602-16-043917 · form4.xml · nonDerivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,873 Read SEC document |
| February 26, 2016 Filed Feb 29, 2016 22:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,650 | $20.71 | $137,688.25 |
DisclosureSEC source: 0001127602-16-043917 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2015 Filed Jan 4, 2016 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 8.8638 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-016952 · edgar.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,114.7376 Underlying: Common Stock · 8.8638 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| December 01, 2015 Filed Dec 3, 2015 23:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Shares · Derivative | 2,105.8737 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-015783 · edgar.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,105.8737 Underlying: Common Stock · 2,105.8737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F3 · shares: An aggregate of 2105.8737 shares were reported in Table II when reporting person acquired the phantom shares. The fractional share of 1.8737 was paid out in cash in connection with the conversion into shares of common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| December 01, 2015 Filed Dec 3, 2015 23:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-015783 · edgar.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. Read SEC document |
| September 29, 2015 Filed Oct 1, 2015 20:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 18.781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-013510 · edgar.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,211.7476 Underlying: Common Stock · 18.781 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| August 28, 2015 Filed Aug 31, 2015 22:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001179110-15-012782 · edgar.xml · derivative · entry 3 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 80,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| August 28, 2015 Filed Aug 31, 2015 22:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 21,000 | $106.96 | $2,246,160.00 |
DisclosureSEC source: 0001179110-15-012782 · edgar.xml · nonDerivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,769 Read SEC document |
| August 28, 2015 Filed Aug 31, 2015 22:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 80,000 | $20.71 | $1,656,400.00 |
DisclosureSEC source: 0001179110-15-012782 · edgar.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2015 Filed Jul 1, 2015 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 15.5583 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-010622 · edgar.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,192.9666 Underlying: Common Stock · 15.5583 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 06, 2015 Filed May 7, 2015 21:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 5,167 | $0.00 Strike: $102.27 | $0.00 |
DisclosureSEC source: 0001179110-15-007270 · edgar.xml · derivative · entry 4 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,167 Underlying: Common Stock · 5,167 shares Expires 2025-05-06 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2015 Filed May 7, 2015 21:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007270 · edgar.xml · derivative · entry 3 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,466 Underlying: Common Stock · 1,466 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 05, 2015 Filed May 7, 2015 21:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007270 · edgar.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 5, 2015. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 5, 2015. Read SEC document |
| May 05, 2015 Filed May 7, 2015 21:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007270 · edgar.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.